BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38629624)

  • 1. Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer.
    Zhang X; Wang X; Wen Y; Chen S; Zhou C; Wu F
    Clin Transl Med; 2024 Apr; 14(4):e1649. PubMed ID: 38629624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine/Chemokine/Growth Factor Levels in Malignant Pleural Effusion of Non-small Cell Lung Cancer.
    Hayama N; Hattori S; Takahashi G; Takahashi F; Takeuchi T; Tanaka J; Horio Y; Takiguchi H; Tomomatsu K; Kitahara A; Takihara T; Niimi K; Oguma T; Asano K
    Tokai J Exp Clin Med; 2020 Dec; 45(4):224-229. PubMed ID: 33300594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
    Thompson JC; Fan R; Black T; Yu GH; Savitch SL; Chien A; Yee SS; Sen M; Hwang WT; Katz SI; Feldman M; Vachani A; Carpenter EL
    Lung Cancer; 2019 Jan; 127():25-33. PubMed ID: 30642547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Profiling of Malignant Pleural Effusion in Metastatic Non-Small-Cell Lung Carcinoma. The Effect of Preanalytical Factors.
    Carter J; Miller JA; Feller-Kopman D; Ettinger D; Sidransky D; Maleki Z
    Ann Am Thorac Soc; 2017 Jul; 14(7):1169-1176. PubMed ID: 28557526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
    Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
    Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
    Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
    Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
    Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.
    Liu X; Lu Y; Zhu G; Lei Y; Zheng L; Qin H; Tang C; Ellison G; McCormack R; Ji Q
    J Clin Pathol; 2013 Dec; 66(12):1065-9. PubMed ID: 23888061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.
    Xiang Z; Deng X; He W; Yang Q; Ni L; Dehghan Shasaltaneh M; Maghsoudloo M; Yang G; Wu J; Imani S; Wen Q
    Ann Med; 2022 Dec; 54(1):1357-1371. PubMed ID: 35543207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
    Schwalk AJ; Ost DE; Saltijeral SN; De La Garza H; Casal RF; Jimenez CA; Eapen GA; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Elamin Y; Zhang J; Roth JA; Swisher S; Heymach JV; Grosu HB
    Chest; 2021 Mar; 159(3):1256-1264. PubMed ID: 33217413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
    Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
    J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer.
    Zhong J; Li X; Bai H; Zhao J; Wang Z; Duan J; An T; Wu M; Wang Y; Wang S; Wang J
    Cytopathology; 2016 Dec; 27(6):433-443. PubMed ID: 27060609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
    Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
    Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of molecular testing for malignant pleural effusion in targeted therapy for advanced non-small cell lung cancer.
    Lin R; Li Y; Lin Y; Tian W; Jiang L; Li J
    Diagn Cytopathol; 2023 Jul; 51(7):397-405. PubMed ID: 37078537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of malignant-associated pleural effusion on endothelial viability, motility and angiogenesis in lung cancer.
    Changchien CY; Chen Y; Chang HH; Chang SY; Tsai WC; Tsai HC; Wang CY; Lee HS; Tsai CL
    Cancer Sci; 2020 Oct; 111(10):3747-3758. PubMed ID: 32706142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.
    Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J
    Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.
    Yu Y; Qian J; Shen L; Ji W; Lu S
    Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient.
    Wang Y; Liu Z; Yin H; Hu J; Zhong S; Chen W; Zhao J
    Gene; 2018 Feb; 644():87-92. PubMed ID: 29097164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion.
    Zhang F; Wang J; Zheng X; Hu L; Chen J; Jiang F; Wang Y
    J Clin Lab Anal; 2018 Oct; 32(8):e22576. PubMed ID: 29797475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients.
    Zhang Z; Ji W; Huang J; Zhang Y; Zhou Y; Zhang J; Dong Y; Yuan T; Yang Q; Ding X; Tang L; Li H; Yin J; Wang Y; Ji T; Fei J; Zhang B; Chen P; Hu H
    Clin Transl Med; 2022 Nov; 12(11):e1072. PubMed ID: 36305631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.